Combined oral contraceptive (COCP)
Oestrogen + progestogen — inhibits ovulation
Overview
A combined oestrogen/progestogen pill that mainly inhibits ovulation. Highly effective with perfect use but typical-use failure ~9%. Offers non-contraceptive benefits (cycle control, ↓ovarian & endometrial cancer) but the oestrogen drives the key contraindications.
Recognise
- Inhibits ovulation; taken 21 days then 7-day break (or continuous/tailored)
- Benefits: predictable lighter periods, helps acne/PMS, ↓ovarian, endometrial & colorectal cancer risk
- Effective immediately if started day 1–5 of cycle (otherwise 7 days extra precautions)
- Small ↑risk of VTE, breast & cervical cancer, and arterial events
Red flags
- UKMEC 4 (absolute): migraine WITH aura; ≥35y AND smoking ≥15/day; BP ≥160/100; history of VTE/known thrombophilia; <6 weeks postpartum + breastfeeding; current breast cancer; major surgery with immobility
Differentials & how to tell them apart
Investigations
BP and BMI before starting (and at review); thorough history for the UKMEC 4 risks (migraine aura, VTE, smoking/age, breast cancer).
Management
Combined pill for a woman wanting cycle control with no oestrogen contraindication
- 1Check BP, BMI and the UKMEC 4 list. If none present, start (day 1–5 = immediate cover).Gate: Migraine WITH aura is UKMEC 4 for the COCP (stroke risk) → use a progestogen-only method instead
- 2≥35y and smoking ≥15/day, or BP ≥160/100, or VTE history → avoid oestrogen; switch to POP/implant/IUS/IUD.
Key points
Enzyme-inducing drugs reduce efficacy. Stop 4 weeks before major surgery with immobility (VTE). Migraine with aura, smoking+age, and VTE history are the classic exam UKMEC 4 traps.
Monitor & prognosis
BP at review; reassess UKMEC risks (new migraine aura, age, smoking).
Rapidly reversible; fertility returns quickly on stopping.
Source: FSRH UKMEC 2016; FSRH CHC guidance